Johnson & Johnson $JNJ Shares Acquired by Robinhood Asset Management LLC

Key Points

• Robinhood Asset Management increased its Johnson & Johnson position by 24.5% in the second quarter, bringing its holdings to 42,812 shares valued at approximately $10.9 million. Institutional investors collectively own 69.55% of JNJ.
• Johnson & Johnson exceeded quarterly expectations, reporting adjusted EPS of $2.90 and revenue of $25.31 billion, while revenue rose 6.6% year over year. The company reaffirmed fiscal 2026 EPS guidance of $11.60–$11.75.
• The company declared a quarterly dividend of $1.34 per share, equivalent to a 1.9% annualized yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $272.83, although insiders sold 63,972 shares worth $16.25 million during the latest quarter.

Robinhood Asset Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 24.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,812 shares of the company's stock after buying an additional 8,428 shares during the period. Robinhood Asset Management LLC's holdings in Johnson & Johnson were worth $10,873,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Blueline Advisors LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $25,000. Cresta Advisors Ltd. purchased a new position in Johnson & Johnson in the fourth quarter valued at about $26,000. Bay Harbor Wealth Management LLC grew its stake in Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock valued at $31,000 after purchasing an additional 49 shares in the last quarter. Semmax Financial Advisors Inc. grew its stake in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock valued at $31,000 after purchasing an additional 72 shares in the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. increased its holdings in Johnson & Johnson by 946.7% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 157 shares of the company's stock worth $32,000 after purchasing an additional 142 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 63,972 shares of company stock valued at $16,245,605. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $275.63 on Thursday. Johnson & Johnson has a 52 week low of $173.33 and a 52 week high of $281.07. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The firm has a market cap of $664.25 billion, a price-to-earnings ratio of 31.94, a PEG ratio of 2.59 and a beta of 0.24. The stock has a 50 day moving average of $260.90 and a 200-day moving average of $244.61.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business's revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio (DPR) is presently 62.11%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: UBS initiated coverage of Johnson & Johnson (JNJ) with a Buy rating and a $320 target, reflecting expectations that the company’s pharmaceutical pipeline can support stronger growth. J&J Jumps as UBS Lifts Its Target to $320
• Positive Sentiment: Healthcare stocks broadly moved higher, with the NYSE Healthcare Index gaining 0.7%, creating a favorable backdrop for JNJ and other defensive healthcare names. Sector Update: Healthcare Stocks Advance Wednesday
• Positive Sentiment: Management will participate in a Deutsche Bank Healthcare Summit fireside chat on September 17. The event could provide additional commentary on the drug pipeline, growth outlook and capital allocation, although no new financial guidance was announced. Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on JNJ shares. Wall Street Zen cut Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Citigroup lifted their price target on shares of Johnson & Johnson from $285.00 to $298.00 and gave the stock a "buy" rating in a research note on Wednesday, July 8th. Bank of America upped their price target on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a "neutral" rating in a report on Friday, July 10th. HSBC set a $290.00 price objective on shares of Johnson & Johnson and gave the stock a "buy" rating in a report on Monday, July 6th. Finally, Wells Fargo & Company boosted their target price on shares of Johnson & Johnson from $272.00 to $282.00 and gave the stock an "overweight" rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $272.83.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source